Cytovation ASA

📍 Bergen, Norway🗓 Founded 2014👥 10 employees💰 Last funded Jan 2022
Pharmaceutical Manufacturing🌐 cytovation.com
Website LinkedIn
Cytovation is a clinical stage biotech developing CyPep-1, the first synthetic peptide engineered to selectively target tumor cell membranes based on their altered molecular composition. CyPep-1 lyses the cell membranes, exposes antigenic material from within the cancer cells, and induces a tumor-specific immune response. The described mode of action is effective across cancer types and highly synergistic with checkpoint inhibitors. CyPep-1 has entered clinical development in Q1 2019.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2014
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Cytovation ASA?
Cytovation ASA has 1 investors on record on gritt.io and 1 late-stage investors.
When did Cytovation ASA last raise funding?
The most recent investment in Cytovation ASA recorded on gritt.io was in January 2022.
When was Cytovation ASA founded?
Cytovation ASA was founded in 2014.
What industry is Cytovation ASA in?
Cytovation ASA operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Cytovation ASA based?
Cytovation ASA is headquartered in Bergen, Norway.